A randomized phase II dose finding study of lenalidomide [Revlimid] and melphalan in patients with previously untreated multiple myeloma.
Phase of Trial: Phase II
Latest Information Update: 28 Mar 2016
At a glance
- Drugs Lenalidomide (Primary) ; Melphalan (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions
- 21 Sep 2013 Additional lead trial centre identified as reported by ClinicalTrials.gov.
- 16 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 Mar 2010 Actual end date (Jun 2008) added as reported by ClinicalTrials.gov.